drtbear1967
Musclechemistry Board Certified Member
Since I know everyone here loves stimulants, I thought I would talk about a lesser known one that is starting to pop up in some products.
Higenamine is an interesting structure. At first glance, it doesn't look like your typical "amphetamine structure" but it's actually a amalgamation of the amino acid tyrosine and dopamine. Higenamine is a beta-2 agonist, just like ephedrine and Synephrine, as well as clenbuterol. Higenamine stimulates cycloadenosine monophosphate(cAMP) production via activating the enzyme adenylate cyclase. cAMP is responsible for glucose and lipid metabolism, as well as increasing norepinephrine levels in the cell. There's not a whole lot of human data, but I read a a study using higenamine, caffeine and yohimbine.
The results showed an increase in energy expenditure and concentration of free fatty acids in the blood, which is indicative of fat burning. Higenamine has a very fast onset, around 7 minutes which is faster than other beta 2 agonists. More human data is needed, but it shows promise in an industry that is constantly losing potent stimulants(DMAA, DMBA, ephedrine, methylsynephrine, BMPEA, and on and on and on)
Higenamine is an interesting structure. At first glance, it doesn't look like your typical "amphetamine structure" but it's actually a amalgamation of the amino acid tyrosine and dopamine. Higenamine is a beta-2 agonist, just like ephedrine and Synephrine, as well as clenbuterol. Higenamine stimulates cycloadenosine monophosphate(cAMP) production via activating the enzyme adenylate cyclase. cAMP is responsible for glucose and lipid metabolism, as well as increasing norepinephrine levels in the cell. There's not a whole lot of human data, but I read a a study using higenamine, caffeine and yohimbine.
The results showed an increase in energy expenditure and concentration of free fatty acids in the blood, which is indicative of fat burning. Higenamine has a very fast onset, around 7 minutes which is faster than other beta 2 agonists. More human data is needed, but it shows promise in an industry that is constantly losing potent stimulants(DMAA, DMBA, ephedrine, methylsynephrine, BMPEA, and on and on and on)
Last edited:
